NASDAQ$HOLX
Hologic Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Hologic's financial performance was announced for Q2 2024, with revenue of $1,017.8 million and GAAP diluted EPS of $0.72. Revenue and non-GAAP diluted EPS exceeded guidance.
Hologic announced its Q2 2024 financial results, with revenue reaching $1,017.8 million. The company's GAAP diluted EPS was $0.72, and non-GAAP diluted EPS was $1.03. Revenue and non-GAAP diluted EPS exceeded the company's guidance. Total company organic revenue, excluding COVID-19, grew by 4.9% in constant currency.
- Revenue was $1,017.8 million, a decrease of (0.8%) year-over-year, driven by lower COVID-19 assay sales.
- Excluding COVID-19 revenues, total organic revenue grew 5.0%, or 4.9% on a constant currency basis.
- Diagnostics revenue decreased (3.1%), but excluding COVID-19 revenues, it grew 9.8% on an organic, constant currency basis.
- Surgical revenue grew 7.7%, driven by strong results from MyoSure and Fluent Fluid Management.
Headline financials
Revenue & EPS history
Hologic · Revenue · Quarterly
$1.02B
Revenue by segment
Hologic · $769M total across 2 segments · Q4 2023
- Diagnostics$416M-20.1%54.1%
- Breast Health$353M+28.2%45.9%
Forward guidance
Hologic provided financial guidance for Q3 and full-year fiscal 2024, anticipating continued strong performance and raising the full-year revenue midpoint in constant currency and EPS guidance.
Tailwinds
- The guidance is based on a full year non-GAAP tax rate of approximately 19.75%.
- Diluted shares outstanding are expected to be approximately 238 million for the full year.
- Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2024 as in fiscal 2023.
- Organic revenue guidance for fiscal 2024 is in constant currency and excludes the divested Blood Screening and SSI ultrasound imaging businesses.
- Organic revenue excluding COVID-19 is in constant currency and excludes COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in Diagnostics.
Headwinds
- Fiscal 2024 has four fewer selling days compared to fiscal 2023.
- The impact of the four fewer selling days is estimated to be a headwind of more than 100 bps for the full year.
- Q3 2024 revenue is expected to be between $992.5 million and $1,007.5 million.
- GAAP EPS for Q3 2024 is projected to be between $0.80 and $0.87.
- Non-GAAP EPS for Q3 2024 is expected to be between $0.98 and $1.05.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-0.5%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.1%
Avg return
30 days after
49%
35 / 72 earnings
Positive
+12.3%
Q3 2020
Best reaction
-11.4%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.0% | -0.6% | +0.7% | |
| Q4 2025 | +0.1% | +0.1% | +0.9% | |
| Q3 2025 | +2.8% | +4.4% | +3.3% | |
| Q2 2025 | -5.6% | -3.2% | +8.5% | |
| Q1 2025 | -10.1% | -11.4% | -11.3% | |
| Q4 2024 | -4.3% | -4.3% | -6.6% | |
| Q3 2024 | +4.9% | +6.4% | +2.2% | |
| Q2 2024 | +0.3% | -0.2% | -3.3% | |
| Q1 2024 | -2.7% | -0.4% | -1.1% | |
| Q4 2023 | +5.7% | +5.4% | +0.1% | |
| Q3 2023 | -5.1% | -5.9% | -5.4% | |
| Q2 2023 | -2.4% | -2.6% | -8.3% | |
| Q1 2023 | +3.8% | +3.6% | -1.1% | |
| Q4 2022 | +10.8% | +12.4% | +13.8% | |
| Q3 2022 | +1.0% | +1.3% | -3.4% | |
| Q2 2022 | +1.2% | +3.4% | +9.8% | |
| Q1 2022 | +4.0% | +3.8% | +2.4% | |
| Q4 2021 | -3.3% | -5.9% | -0.3% | |
| Q3 2021 | +2.3% | +5.0% | +9.7% | |
| Q2 2021 | -9.1% | -9.9% | -13.4% | |
| Q1 2021 | +1.7% | +11.2% | -3.3% | |
| Q4 2020 | +6.6% | -5.0% | +1.7% | |
| Q3 2020 | +12.3% | +14.8% | -2.8% | |
| Q2 2020 | +2.9% | +2.6% | +8.9% | |
| Q1 2020 | -0.7% | -1.8% | -13.7% | |
| Q4 2019 | -4.0% | +8.8% | +10.3% | |
| Q3 2019 | -1.3% | -6.5% | -4.1% | |
| Q2 2019 | -0.1% | +0.7% | -5.1% | |
| Q1 2019 | +0.6% | -0.5% | +8.6% | |
| Q4 2018 | +4.9% | +1.2% | +3.7% | |
| Q3 2018 | -3.5% | -1.9% | -7.5% | |
| Q2 2018 | -6.9% | -6.8% | -3.9% | |
| Q1 2018 | -6.7% | -6.6% | -2.2% | |
| Q4 2017 | +0.4% | +2.9% | +8.1% | |
| Q3 2017 | -9.3% | -11.3% | -12.5% | |
| Q2 2017 | -4.3% | -5.1% | -2.0% | |
| Q1 2017 | -2.6% | -2.9% | +1.8% | |
| Q4 2016 | +4.3% | +8.5% | +6.3% | |
| Q3 2016 | +3.9% | +5.8% | +5.3% | |
| Q2 2016 | -10.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +8.6% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | +5.1% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | +8.1% | — | — | |
| Q1 2014 | -5.9% | — | — | |
| Q4 2013 | -6.9% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -11.4% | — | — | |
| Q1 2012 | +5.2% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q3 2011 | -3.9% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q2 2009 | +2.9% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q4 2009 | +2.9% | — | — | |
| Q3 2009 | -3.0% | — | — | |
| Q3 2008 | -3.0% | — | — | |
| Q4 2008 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro